Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis.
Many human atherosclerotic lesions, showing no evidence of fissure or ulceration, contain a large amount of fibrin which may be in the form of mural thrombus on the intact surface of the plaque, in layers within the fibrous cap, in the lipid-rich centre, or diffusely distributed throughout the plaque. Small mural thrombi are invaded by SMCs and collagen is deposited in patterns closely resembling the early proliferative gelatinous lesions. In experimental animals, thrombi are converted into lesions with all the characteristics of fibrous plaques, and in saphenous-vein bypass grafts, fibrin deposition is the main cause of wall thickening and occlusion. There seems little doubt that fibrin deposition can both initiate atherogenesis and contribute to the growth of plaques. Epidemiological studies indicate that increased levels of fibrinogen and clotting activity are associated with accelerated atherosclerosis, and although blood fibrinolytic activity has given inconsistent results, in arterial intima both fibrinolytic activity and plasminogen concentration are decreased in cardiovascular disease. Fibrin may stimulate cell proliferation by providing a scaffold along which cells migrate, and by binding fibronectin, which stimulates cell migration and adhesion. Fibrin degradation products, which are present in the intima, may stimulate mitogenesis and collagen synthesis, attract leukocytes, and alter endothelial permeability and vascular tone. In the advanced plaque fibrin may be involved in the tight binding of LDL and accumulation of lipid. Thus there is extensive evidence that enhanced blood coagulation is a risk factor not only for thrombotic occlusion, but also for atherogenesis. Enhanced blood coagulation frequently coexists with hyperlipidaemia and, together, these may have a synergistic effect on atherogenesis.
D000818:Animals; D001161:Arteriosclerosis / Q000209:etiology* / Q000473:pathology / Q000503:physiopathology; D003327:Coronary Disease / Q000209:etiology; D004195:Disease Models, Animal; D005337:Fibrin / Q000502:physiology*; D005338:Fibrin Fibrinogen Degradation Products / Q000502:physiology*; D005340:Fibrinogen / Q000502:physiology*; D006487:Hemostasis; D006801:Humans; D008077:Lipoproteins, LDL / Q000502:physiology; D009131:Muscle, Smooth, Vascular / Q000473:pathology / Q000503:physiopathology; D012306:Risk; D013927:Thrombosis / Q000209:etiology
D005338:Fibrin Fibrinogen Degradation Products; D008077:Lipoproteins, LDL; D005337:Fibrin; D005340:Fibrinogen